HUTCHMED (CHINA) LIMITED Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 9, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2021 annual results of HUTCHMED on March 3, 2022, the following awards granted under the Long Term Incentive Plan ("LTIP") on March 15, 2017 and April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 8, 2022:-
Award Holders | Number of American depositary shares ("ADS") |
Person Discharging Managerial Responsibilities | |
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | 18,770 |
Mr Johnny Cheng (Executive Director and Chief Financial Officer) | 4,198 |
Total | 22,968 |
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
| (a) | Dr Weiguo Su |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Dr Weiguo Su |
2 | Reason for the notification | |
a) | Position/status | Executive Director, Chief Executive Officer and Chief Scientific Officer |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | HUTCHMED (China) Limited |
b) | LEI | 2138006X34YDQ6OBYE79 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | ADS each representing five Ordinary Shares of US$0.10 |
Identification code | ADS ISIN: US44842L1035 | |
b) | Nature of the transaction | (i) Vesting of awards granted on March 15, 2017 under HUTCHMED's LTIP (ii) Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP |
c) | Price(s) and volume(s) | |
Price(s) | Volume(s) | |
(i) | Nil | 3,754 ADS |
(ii) | Nil | 15,016 ADS |
d) | Aggregated information | N/A |
- Aggregated volume | ||
- Price | ||
e) | Date of the transaction | 2022-03-08 |
f) | Place of the transaction | Outside a trading venue |
| (b) | Mr Johnny Cheng |
HIDDEN_ROW | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Mr Johnny Cheng |
2 | Reason for the notification | |
a) | Position/status | Executive Director and Chief Financial Officer |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | HUTCHMED (China) Limited |
b) | LEI | 2138006X34YDQ6OBYE79 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | ADS each representing five Ordinary Shares of US$0.10 |
Identification code | ADS ISIN: US44842L1035 | |
b) | Nature of the transaction | Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP |
c) | Price(s) and volume(s) | |
Price(s) | Volume(s) | |
Nil | 4,198 ADS | |
d) | Aggregated information | N/A |
- Aggregated volume | ||
- Price | ||
e) | Date of the transaction | 2022-03-08 |
f) | Place of the transaction | Outside a trading venue |
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | |
Mark Lee, Senior Vice President | +852 2121 8200 |
Annie Cheng, Vice President | +1 (973) 567 3786 |
Media Enquiries | |
Americas - Brad Miles, |
+1 (917) 570 7340 (Mobile) |
Europe - Ben Atwell / Alex Shaw, |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
Asia - Zhou Yi, |
+852 9783 6894 (Mobile) |
Nominated Advisor | |
Atholl Tweedie / Freddy Crossley, | +44 (20) 7886 2500 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
HUTCHMED (China) Ltd. published this content on 09 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 March 2022 11:51:08 UTC.
